Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Recommendation of “Moderate Buy” by Analysts

Twist Bioscience Corporation (NASDAQ:TWST) has earned an average rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $71.60.

Several equities analysts have commented on the company. Piper Sandler assumed coverage on Twist Bioscience in a report on Thursday, June 11th. They set an “overweight” rating and a $85.00 price target on the stock. Robert W. Baird increased their price target on Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Tuesday, May 5th. TD Cowen increased their price target on Twist Bioscience from $68.00 to $89.00 and gave the company a “buy” rating in a report on Monday. Barclays increased their price target on Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Finally, UBS Group set a $89.00 price target on Twist Bioscience in a report on Monday.

Twist Bioscience Trading Up 5.1%

Shares of TWST stock opened at $84.95 on Wednesday. Twist Bioscience has a 12 month low of $23.30 and a 12 month high of $86.94. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $60.98 and its two-hundred day moving average is $48.30. The company has a market cap of $5.29 billion, a PE ratio of -63.87 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The company had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. During the same quarter last year, the business earned ($0.66) EPS. The company’s revenue for the quarter was up 19.3% on a year-over-year basis. Equities analysts predict that Twist Bioscience will post -2.02 EPS for the current year.

Insiders Place Their Bets

In related news, Director Melissa A. Starovasnik sold 500 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $61.83, for a total transaction of $30,915.00. Following the transaction, the director owned 25,222 shares of the company’s stock, valued at approximately $1,559,476.26. The trade was a 1.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jan Johannessen sold 12,000 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total transaction of $673,440.00. Following the transaction, the director owned 17,754 shares of the company’s stock, valued at approximately $996,354.48. The trade was a 40.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,170 shares of company stock valued at $1,948,964 in the last 90 days. 3.08% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC acquired a new position in Twist Bioscience during the 1st quarter valued at $7,128,000. Western Wealth Management LLC acquired a new position in Twist Bioscience during the 1st quarter valued at $31,000. Flax Pond Capital LLC acquired a new position in Twist Bioscience during the 1st quarter valued at $76,000. Bank of America Corp DE raised its stake in Twist Bioscience by 46.3% during the 1st quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock valued at $27,764,000 after purchasing an additional 184,907 shares during the last quarter. Finally, Oddo BHF Asset Management Sas raised its stake in Twist Bioscience by 7.6% during the 1st quarter. Oddo BHF Asset Management Sas now owns 145,960 shares of the company’s stock valued at $6,936,000 after purchasing an additional 10,310 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.